{"id":39193,"date":"2024-08-30T14:23:00","date_gmt":"2024-08-30T14:23:00","guid":{"rendered":"https:\/\/indogenmed.org\/resource\/osimertinib-as-a-first-line-therapy-key-approvals-and-benefits-for-lung-cancer-patients\/"},"modified":"2026-07-10T08:45:24","modified_gmt":"2026-07-10T08:45:24","slug":"osimertinib-first-line-therapy-approvals-for-lung-cancer","status":"publish","type":"post","link":"https:\/\/indogenmed.org\/ja\/resource\/osimertinib-first-line-therapy-approvals-for-lung-cancer\/","title":{"rendered":"\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u3092\u4e00\u6b21\u6cbb\u7642\u3068\u3057\u3066\uff1a\u80ba\u304c\u3093\u60a3\u8005\u306b\u5bfe\u3059\u308b\u4e3b\u8981\u306a\u627f\u8a8d\u3068\u5229\u70b9"},"content":{"rendered":"<p><a href=\"\/molecule\/osimertinib\/\" target=\"_blank\" rel=\"noopener\">\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6<\/a>\u306f\u3001EGFR\u5909\u7570\u975e\u5c0f\u7d30\u80de<a href=\"\/ja\/medicine\/lung-cancer\/\">\u80ba\u304c\u3093<\/a>\uff08NSCLC\uff09\u306e\u6cbb\u7642\u306b\u304a\u3051\u308b\u9769\u65b0\u7684\u306a\u85ac\u5264\u3067\u3042\u308a\u3001\u816b\u760d\u5b66\u306e\u5206\u91ce\u3067\u6ce8\u76ee\u3092\u96c6\u3081\u3066\u3044\u307e\u3059\u3002\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u306f\u30bf\u30b0\u30ea\u30c3\u30bd\u3068\u3057\u3066\u3082\u77e5\u3089\u308c\u3066\u3044\u307e\u3059\u3002\u5f53\u521d\u306f\u8010\u6027\u306e\u3042\u308b\u80ba\u304c\u3093\u60a3\u8005\u306b\u5bfe\u3059\u308b\u4e8c\u6b21\u6cbb\u7642\u3068\u3057\u3066\u958b\u767a\u3055\u308c\u307e\u3057\u305f\u304c\u3001\u8fd1\u5e74\u3067\u306f\u4e00\u6b21\u6cbb\u7642\u3068\u3057\u3066\u306e\u91cd\u8981\u6027\u304c\u9ad8\u307e\u3063\u3066\u3044\u307e\u3059\u3002\u7279\u5b9a\u306e\u5909\u7570\u3092\u6a19\u7684\u3068\u3057\u3001\u751f\u5b58\u671f\u9593\u3092\u5ef6\u9577\u3059\u308b\u80fd\u529b\u3092\u6301\u3064\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u306f\u3001EGFR\u5909\u7570\u80ba\u304c\u3093\u306e\u7ba1\u7406\u3092\u5909\u9769\u3057\u3066\u3044\u307e\u3059\u30022024\u5e74\u306b\u304a\u3044\u3066\u3082\u3001\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u3092\u4e00\u6b21\u6cbb\u7642\u3068\u3057\u3066\u4f7f\u7528\u3059\u308b\u50be\u5411\u306f\u3001\u91cd\u8981\u306a\u81e8\u5e8a\u8a66\u9a13\u3068\u66f4\u65b0\u3055\u308c\u305fFDA\u627f\u8a8d\u306b\u3088\u3063\u3066\u88cf\u4ed8\u3051\u3089\u308c\u3001\u4e0a\u6607\u3057\u7d9a\u3051\u3066\u3044\u307e\u3059\u3002<\/p>\n<h2>\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u3068\u306f\uff1f<\/h2>\n<p>\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\uff08<a href=\"\/ja\/product\/tagrisso-80mg-tablets\/\" target=\"_blank\" rel=\"noopener\">\u30bf\u30b0\u30ea\u30c3\u30bd<\/a>\uff09\u306f\u3001\u4e0a\u76ae\u6210\u9577\u56e0\u5b50\u53d7\u5bb9\u4f53\uff08EGFR\uff09\u306e\u5909\u7570\u3092\u7279\u7570\u7684\u306b\u6a19\u7684\u3068\u3059\u308b\u3088\u3046\u306b\u8a2d\u8a08\u3055\u308c\u305f\u7b2c\u4e09\u4e16\u4ee3\u306e\u30c1\u30ed\u30b7\u30f3\u30ad\u30ca\u30fc\u30bc\u963b\u5bb3\u5264\uff08TKI\uff09\u3067\u3059\u3002\u3053\u308c\u3089\u306e\u5909\u7570\u306f\u3001\u7c73\u56fd\u3067\u306f\u80ba\u304c\u3093\u75c7\u4f8b\u306e\u7d0410\uff5e15\uff05\u3001\u30a2\u30b8\u30a2\u3067\u306f\u6700\u592730\uff5e50\uff05\u306b\u767a\u751f\u3057\u307e\u3059\u3002\u3053\u308c\u3089\u306e\u5909\u7570\u306f\u304c\u3093\u7d30\u80de\u3092\u7a4d\u6975\u7684\u306b\u5897\u6b96\u30fb\u62e1\u6563\u3055\u305b\u3001\u6cbb\u7642\u3092\u56f0\u96e3\u306b\u3057\u307e\u3059\u3002\u521d\u671f\u4e16\u4ee3\u306eEGFR\u963b\u5bb3\u5264\u3068\u306f\u7570\u306a\u308a\u3001\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u306fEGFR\u611f\u53d7\u6027\u5909\u7570\u3068T790M\u8010\u6027\u5909\u7570\u306e\u4e21\u65b9\u306b\u52b9\u679c\u304c\u3042\u308a\u3001\u9032\u884c\u80ba\u304c\u3093\u60a3\u8005\u306b\u3068\u3063\u3066\u91cd\u8981\u306a\u9078\u629e\u80a2\u3068\u306a\u3063\u3066\u3044\u307e\u3059\u3002<\/p>\n<h2>\u8ee2\u63db\uff1a\u4e8c\u6b21\u6cbb\u7642\u304b\u3089\u4e00\u6b21\u6cbb\u7642\u3078<\/h2>\n<p>\u5f53\u521d\u3001<a href=\"\/ja\/resource\/osimertinib-side-effects-common-long-term-risks\/\">\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6<\/a>\u306f\u3001\u7279\u306bT790M\u5909\u7570\u3092\u6301\u3064\u3001\u4ee5\u524d\u306e\u6cbb\u7642\u306b\u8010\u6027\u304c\u751f\u3058\u305f\u60a3\u8005\u306b\u5bfe\u3059\u308b\u4e8c\u6b21\u6cbb\u7642\u3068\u3057\u3066\u4f7f\u7528\u3055\u308c\u3066\u3044\u307e\u3057\u305f\u3002\u3057\u304b\u3057\u30012018\u5e74\u306bFDA\u306f\u3001\u91cd\u8981\u306aFLAURA\u8a66\u9a13\u306e\u7d50\u679c\u306b\u57fa\u3065\u304d\u3001EGFR\u5909\u7570\u975e\u5c0f\u7d30\u80de\u80ba\u304c\u3093\u60a3\u8005\u306b\u5bfe\u3059\u308b\u4e00\u6b21\u6cbb\u7642\u3068\u3057\u3066\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u3092\u627f\u8a8d\u3057\u307e\u3057\u305f\u3002<\/p>\n<h2>FLAURA\u8a66\u9a13\uff1a\u4e00\u6b21\u6cbb\u7642\u3078\u306e\u9053\u3092\u958b\u304f<\/h2>\n<p>\t\t\tFLAURA\u8a66\u9a13\u306f\u3001\u80ba\u304c\u3093\u6cbb\u7642\u306b\u304a\u3051\u308b\u753b\u671f\u7684\u306a\u3082\u306e\u3067\u3057\u305f\u3002\u3053\u306e\u8a66\u9a13\u3067\u306f\u3001EGFR\u5909\u7570NSCLC\u60a3\u8005\u3092\u5bfe\u8c61\u306b\u3001\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u3068\u6a19\u6e96\u7684\u306aEGFR-TKI\uff08\u30b2\u30d5\u30a3\u30c1\u30cb\u30d6\u3084\u30a8\u30eb\u30ed\u30c1\u30cb\u30d6\u306a\u3069\uff09\u3092\u4e00\u6b21\u6cbb\u7642\u3068\u3057\u3066\u6bd4\u8f03\u3057\u307e\u3057\u305f\u3002\u305d\u306e\u7d50\u679c\u306f\u76ee\u899a\u307e\u3057\u3044\u3082\u306e\u3067\u3057\u305f\u3002<\/p>\n<ul>\n<li>\u7121\u5897\u60aa\u751f\u5b58\u671f\u9593\uff08PFS\uff09\u306e\u4e2d\u592e\u5024\u306f\u3001\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u7fa4\u306718.9\u30f6\u6708\u3068\u3001\u6a19\u6e96\u6cbb\u7642\u7fa4\u306e10.2\u30f6\u6708\u3088\u308a\u3082\u6709\u610f\u306b\u9577\u304b\u3063\u305f\u3002<\/li>\n<li>\u5168\u751f\u5b58\u671f\u9593\uff08OS\uff09\u3082\u5927\u5e45\u306a\u6539\u5584\u3092\u793a\u3057\u3001\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u306f\u6b7b\u4ea1\u30ea\u30b9\u30af\u309252%\u6e1b\u5c11\u3055\u305b\u307e\u3057\u305f\u3002<\/li>\n<li>\u3053\u308c\u3089\u306e\u7d50\u679c\u306b\u3088\u308a\u3001FDA\u306fEGFR\u5909\u7570NSCLC\u60a3\u8005\u306b\u5bfe\u3059\u308b\u4e00\u6b21\u6cbb\u7642\u3068\u3057\u3066\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u3092\u627f\u8a8d\u3057\u3001\u500b\u5225\u5316\u304c\u3093\u6cbb\u7642\u306e\u65b0\u6642\u4ee3\u3092\u753b\u3057\u307e\u3057\u305f\u3002<\/li>\n<\/ul>\n<h2>\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6 vs. \u305d\u306e\u4ed6\u306eEGFR\u963b\u5bb3\u5264<\/h2>\n<table style=\"height: 277px\" width=\"1509\">\n<tbody>\n<tr>\n<td><strong>\u7279\u5fb4<\/strong><\/td>\n<td><strong>\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\uff08\u30bf\u30b0\u30ea\u30c3\u30bd\uff09<\/strong><\/td>\n<td><strong>\u30b2\u30d5\u30a3\u30c1\u30cb\u30d6\uff08\u30a4\u30ec\u30c3\u30b5\uff09<\/strong><\/td>\n<td><strong>\u30a8\u30eb\u30ed\u30c1\u30cb\u30d6\uff08\u30bf\u30eb\u30bb\u30d0\uff09<\/strong><\/td>\n<td><strong>\u30a2\u30d5\u30a1\u30c1\u30cb\u30d6\uff08\u30b8\u30aa\u30c8\u30ea\u30d5\uff09<\/strong><\/td>\n<\/tr>\n<tr>\n<td>\u6a19\u7684<\/td>\n<td>EGFR\uff08T790M\u5909\u7570\uff09<\/td>\n<td>EGFR<\/td>\n<td>EGFR<\/td>\n<td>EGFR + HER2<\/td>\n<\/tr>\n<tr>\n<td>FDA\u627f\u8a8d<\/td>\n<td>\u3042\u308a\uff082015\u5e74\uff09<\/td>\n<td>\u3042\u308a\uff082003\u5e74\uff09<\/td>\n<td>\u3042\u308a\uff082004\u5e74\uff09<\/td>\n<td>\u3042\u308a\uff082013\u5e74\uff09<\/td>\n<\/tr>\n<tr>\n<td>\u4e00\u6b21\u6cbb\u7642\u3067\u306e\u4f7f\u7528<\/td>\n<td>\u3042\u308a\uff08NSCLC\u5411\u3051\uff09<\/td>\n<td>\u3042\u308a<\/td>\n<td>\u3042\u308a<\/td>\n<td>\u3042\u308a<\/td>\n<\/tr>\n<tr>\n<td>\u5168\u751f\u5b58\u671f\u9593\uff08\u4e2d\u592e\u5024\uff09<\/td>\n<td>38.6\u30f6\u6708\uff08FLAURA\u8a66\u9a13\uff09<\/td>\n<td>18.8\u30f6\u6708\uff08IPASS\u8a66\u9a13\uff09<\/td>\n<td>19.3\u30f6\u6708\uff08OPTIMAL\u8a66\u9a13\uff09<\/td>\n<td>28.2\u30f6\u6708\uff08LUX-Lung 7\uff09<\/td>\n<\/tr>\n<tr>\n<td>PFS\uff08\u7121\u5897\u60aa\u751f\u5b58\u671f\u9593\uff09<\/td>\n<td>18.9\u30f6\u6708\uff08FLAURA\uff09<\/td>\n<td>9.5\u30f6\u6708\uff08IPASS\uff09<\/td>\n<td>13.1\u30f6\u6708\uff08OPTIMAL\uff09<\/td>\n<td>11.0\u30f6\u6708\uff08LUX-Lung 7\uff09<\/td>\n<\/tr>\n<tr>\n<td>\u526f\u4f5c\u7528<\/td>\n<td>\u4e0b\u75e2\u3001\u767a\u75b9\u3001\u76ae\u819a\u4e7e\u71e5<\/td>\n<td>\u4e0b\u75e2\u3001\u767a\u75b9<\/td>\n<td>\u4e0b\u75e2\u3001\u767a\u75b9<\/td>\n<td>\u4e0b\u75e2\u3001\u767a\u75b9<\/td>\n<\/tr>\n<tr>\n<td>\u4e00\u822c\u7684\u306a\u7528\u91cf<\/td>\n<td>80 mg 1\u65e51\u56de<\/td>\n<td>250 mg 1\u65e51\u56de<\/td>\n<td>150 mg 1\u65e51\u56de<\/td>\n<td>40 mg 1\u65e51\u56de<\/td>\n<\/tr>\n<tr>\n<td>\u4e3b\u306a\u7528\u9014<\/td>\n<td>EGFR T790M\u5909\u7570\u3092\u4f34\u3046\u9032\u884c\u6027\u307e\u305f\u306f\u8ee2\u79fb\u6027NSCLC<\/td>\n<td>EGFR\u5909\u7570\u306b\u5bfe\u3059\u308b\u4e00\u6b21\u6cbb\u7642<\/td>\n<td>EGFR\u5909\u7570\u306b\u5bfe\u3059\u308b\u4e00\u6b21\u6cbb\u7642<\/td>\n<td>EGFR\u5909\u7570\u304a\u3088\u3073HER2\u306b\u5bfe\u3059\u308b\u4e00\u6b21\u6cbb\u7642<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u3092\u4e00\u6b21\u6cbb\u7642\u3068\u3057\u3066\u4f7f\u7528\u3059\u308b\u5229\u70b9<\/h2>\n<p>\t\t\t\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u3092\u4e00\u6b21\u6cbb\u7642\u3068\u3057\u3066\u4f7f\u7528\u3059\u308b\u5834\u5408\u3001\u3044\u304f\u3064\u304b\u306e\u5229\u70b9\u304c\u3042\u308a\u307e\u3059\u3002<\/p>\n<ul>\n<li>\u6a19\u7684\u3092\u7d5e\u3063\u305f\u4f5c\u7528\uff1a\u5909\u7570\u3057\u305fEGFR\u3092\u9078\u629e\u7684\u306b\u6a19\u7684\u3068\u3057\u3001\u5065\u5eb7\u306a\u7d30\u80de\u3078\u306e\u640d\u50b7\u3092\u8efd\u6e1b\u3057\u307e\u3059\u3002<\/li>\n<li>\u526f\u4f5c\u7528\u306e\u8efd\u6e1b\uff1a\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u306f\u3001\u521d\u671f\u306eEGFR-TKI\u3088\u308a\u3082\u4e00\u822c\u7684\u306b\u5fcd\u5bb9\u6027\u304c\u9ad8\u304f\u3001\u91cd\u7be4\u306a\u526f\u4f5c\u7528\u304c\u5c11\u306a\u3044\u3067\u3059\u3002<\/li>\n<li>\u751f\u5b58\u671f\u9593\u306e\u5ef6\u9577\uff1a\u81e8\u5e8a\u8a66\u9a13\u3067\u793a\u3055\u308c\u3066\u3044\u308b\u3088\u3046\u306b\u3001\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u306f\u5f93\u6765\u306e\u6cbb\u7642\u6cd5\u3068\u6bd4\u8f03\u3057\u3066\u3001\u7121\u5897\u60aa\u751f\u5b58\u671f\u9593\u3068\u5168\u751f\u5b58\u671f\u9593\u306e\u4e21\u65b9\u3092\u5ef6\u9577\u3057\u307e\u3059\u3002<\/li>\n<li>\u4e2d\u67a2\u795e\u7d4c\u7cfb\uff08CNS\uff09\u3078\u306e\u6709\u52b9\u6027\uff1a\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u306f\u8840\u6db2\u8133\u95a2\u9580\u3092\u52b9\u679c\u7684\u306b\u901a\u904e\u3059\u308b\u3053\u3068\u304c\u793a\u3055\u308c\u3066\u304a\u308a\u3001\u8133\u8ee2\u79fb\u306e\u3042\u308b\u60a3\u8005\u306b\u3068\u3063\u3066\u512a\u308c\u305f\u9078\u629e\u80a2\u3068\u306a\u308a\u307e\u3059\u3002<\/li>\n<\/ul>\n<h2>FDA\u627f\u8a8d\u3068\u66f4\u65b0<\/h2>\n<p>2018\u5e74\u306eFDA\u306b\u3088\u308bEGFR\u5909\u7570NSCLC\u60a3\u8005\u306b\u5bfe\u3059\u308b\u4e00\u6b21\u6cbb\u7642\u3068\u3057\u3066\u306e\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u306e\u627f\u8a8d\u306f\u3001\u753b\u671f\u7684\u306a\u6c7a\u5b9a\u3067\u3057\u305f\u3002\u3053\u308c\u306f\u3001EGFR\u5909\u7570\u306e\u6700\u3082\u4e00\u822c\u7684\u306a2\u3064\u306e\u30bf\u30a4\u30d7\u3067\u3042\u308b\u30a8\u30af\u30bd\u30f319\u6b20\u5931\u3068\u30a8\u30af\u30bd\u30f321 L858R\u7f6e\u63db\u5909\u7570\u306e\u4e21\u65b9\u3067\u306e\u4f7f\u7528\u304c\u627f\u8a8d\u3055\u308c\u3066\u3044\u307e\u3059\u3002<br \/>\n\t\t\t2020\u5e74\u306b\u306f\u3001FDA\u306f\u816b\u760d\u5207\u9664\u5f8c\u306eEGFR\u5909\u7570NSCLC\u60a3\u8005\u306b\u5bfe\u3059\u308b\u8853\u5f8c\u88dc\u52a9\u7642\u6cd5\u3092\u542b\u3080\u3088\u3046\u306b\u627f\u8a8d\u3092\u62e1\u5927\u3057\u307e\u3057\u305f\u3002\u3053\u308c\u306f\u3001\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u304c\u73fe\u5728\u3001\u80ba\u304c\u3093\u306e\u6cbb\u7642\u3068\u518d\u767a\u4e88\u9632\u306e\u4e21\u65b9\u306b\u4f7f\u7528\u3055\u308c\u3066\u3044\u308b\u3053\u3068\u3092\u610f\u5473\u3057\u307e\u3059\u3002<\/p>\n<h2>2024\u5e74\u306eFDA\u627f\u8a8d\u66f4\u65b0<\/h2>\n<p>2024\u5e74\u73fe\u5728\u3001FLAURA2\u306a\u3069\u306e\u9032\u884c\u4e2d\u306e\u8a66\u9a13\u3067\u306f\u3001\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u3068\u5316\u5b66\u7642\u6cd5\u3084\u514d\u75ab\u7642\u6cd5\u306a\u3069\u306e\u4ed6\u306e\u6cbb\u7642\u6cd5\u3068\u306e\u4f75\u7528\u304c\u3001\u305d\u306e\u6709\u52b9\u6027\u3092\u3055\u3089\u306b\u9ad8\u3081\u308b\u305f\u3081\u306b\u8abf\u67fb\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u3053\u308c\u3089\u306e\u8a66\u9a13\u7d50\u679c\u306f\u71b1\u5fc3\u306b\u5f85\u305f\u308c\u3066\u304a\u308a\u3001\u8ffd\u52a0\u306eFDA\u627f\u8a8d\u3084\u3001\u3088\u308a\u9032\u884c\u3057\u305f\u6bb5\u968e\u306e\u80ba\u304c\u3093\u306b\u304a\u3051\u308b\u4f7f\u7528\u62e1\u5927\u306b\u3064\u306a\u304c\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002<br \/>\n\t\t\t2024\u5e74\u3001\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\uff08\u30bf\u30b0\u30ea\u30c3\u30bd\uff09\u306f\u3001\u3044\u304f\u3064\u304b\u306e\u91cd\u8981\u306aFDA\u627f\u8a8d\u306b\u3088\u308a\u3001EGFR\u5909\u7570\u975e\u5c0f\u7d30\u80de\u80ba\u304c\u3093\uff08NSCLC\uff09\u306e\u6cbb\u7642\u306b\u304a\u3051\u308b\u5f79\u5272\u3092\u62e1\u5927\u3057\u7d9a\u3051\u3066\u3044\u307e\u3059\u3002\u3053\u308c\u3089\u306e\u66f4\u65b0\u306f\u3001\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u304c\u80ba\u304c\u3093\u306e\u69d8\u3005\u306a\u75c5\u671f\u306e\u60a3\u8005\u306b\u3068\u3063\u3066\u591a\u7528\u9014\u3067\u5b9f\u7528\u7684\u306a\u6cbb\u7642\u9078\u629e\u80a2\u3068\u3057\u3066\u306e\u5730\u4f4d\u3092\u3055\u3089\u306b\u78ba\u56fa\u305f\u308b\u3082\u306e\u306b\u3057\u3066\u3044\u307e\u3059\u3002<br \/>\n\t\t\t2024\u5e742\u6708\uff1aFDA\u306f\u3001FLAURA2\u8a66\u9a13\u306e\u826f\u597d\u306a\u7d50\u679c\u3092\u53d7\u3051\u3001\u5c40\u6240\u9032\u884c\u6027\u307e\u305f\u306f\u8ee2\u79fb\u6027\u306eEGFR\u5909\u7570NSCLC\u60a3\u8005\u306b\u5bfe\u3059\u308b\u30d7\u30e9\u30c1\u30ca\u88fd\u5264\u30d9\u30fc\u30b9\u306e\u5316\u5b66\u7642\u6cd5\u3068\u306e\u4f75\u7528\u3067\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u3092\u627f\u8a8d\u3057\u307e\u3057\u305f\u3002\u3053\u306e\u4f75\u7528\u7642\u6cd5\u3092\u53d7\u3051\u305f\u60a3\u8005\u306ePFS\u4e2d\u592e\u5024\u306f25.5\u30f6\u6708\u3067\u3042\u308a\u3001\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u5358\u5264\u7642\u6cd5\u306e\u5834\u5408\u306e16.7\u30f6\u6708\u3068\u6bd4\u8f03\u3057\u3066\u5ef6\u9577\u3055\u308c\u307e\u3057\u305f\u3002<br \/>\n\t\t\t2024\u5e749\u6708\uff1aFDA\u306f\u3001LAURA\u8a66\u9a13\u306e\u30c7\u30fc\u30bf\u306b\u57fa\u3065\u304d\u3001\u5316\u5b66\u653e\u5c04\u7dda\u7642\u6cd5\u4e2d\u307e\u305f\u306f\u5f8c\u306b\u75c5\u72b6\u304c\u9032\u884c\u3057\u306a\u304b\u3063\u305f\u5c40\u6240\u9032\u884c\u6027\u3001\u5207\u9664\u4e0d\u80fd\u306a\u30b9\u30c6\u30fc\u30b8III NSCLC\u60a3\u8005\u3092\u542b\u3080\u3088\u3046\u306b\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u306e\u9069\u5fdc\u3092\u3055\u3089\u306b\u62e1\u5927\u3057\u307e\u3057\u305f\u3002<br \/>\n\t\t\t\u3053\u308c\u3089\u306e\u627f\u8a8d\u306f\u3001EGFR\u5909\u7570NSCLC\u306e\u6cbb\u7642\u65b9\u6cd5\u306b\u5909\u5316\u3092\u3082\u305f\u3089\u3057\u3001\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u3092\u9032\u884c\u671f\u306e\u75be\u60a3\u3084\u9032\u884c\u3092\u9045\u3089\u305b\u308b\u305f\u3081\u306e\u4f75\u7528\u7642\u6cd5\u306b\u304a\u3051\u308b\u4e3b\u8981\u306a\u9078\u629e\u80a2\u3068\u3057\u3066\u4f4d\u7f6e\u4ed8\u3051\u3066\u3044\u307e\u3059\u3002\u3053\u306e\u5909\u5316\u306f\u3001\u500b\u5225\u5316\u304c\u3093\u6cbb\u7642\u3078\u306e\u7d99\u7d9a\u7684\u306a\u30b3\u30df\u30c3\u30c8\u30e1\u30f3\u30c8\u3068\u3001\u60a3\u8005\u306e\u8ee2\u5e30\u3092\u6539\u5584\u3059\u308b\u4e0a\u3067\u306e\u6a19\u7684\u7642\u6cd5\u306e\u5f79\u5272\u3092\u6d6e\u304d\u5f6b\u308a\u306b\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n<h2>\u8ab2\u984c\u3068\u8003\u616e\u4e8b\u9805<\/h2>\n<p>\u591a\u304f\u306e\u5229\u70b9\u304c\u3042\u308b\u306b\u3082\u304b\u304b\u308f\u3089\u305a\u3001\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u3092\u4e00\u6b21\u6cbb\u7642\u3068\u3057\u3066\u4f7f\u7528\u3059\u308b\u969b\u306b\u306f\u3044\u304f\u3064\u304b\u306e\u8ab2\u984c\u304c\u6b8b\u3063\u3066\u3044\u307e\u3059\u3002<\/p>\n<ul>\n<li>\u8cbb\u7528\uff1a\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u306f\u9ad8\u4fa1\u3067\u3042\u308a\u3001\u5305\u62ec\u7684\u306a\u4fdd\u967a\u306b\u52a0\u5165\u3057\u3066\u3044\u306a\u3044\u60a3\u8005\u306b\u3068\u3063\u3066\u306f\u8cbb\u7528\u8ca0\u62c5\u304c\u61f8\u5ff5\u3055\u308c\u308b\u3053\u3068\u304c\u3042\u308a\u307e\u3059\u3002<\/li>\n<li>\u8010\u6027\u767a\u751f\uff1a\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u306f\u975e\u5e38\u306b\u52b9\u679c\u7684\u3067\u3059\u304c\u3001\u4e00\u90e8\u306e\u60a3\u8005\u306f\u6700\u7d42\u7684\u306b\u85ac\u5264\u306b\u5bfe\u3059\u308b\u8010\u6027\u3092\u7372\u5f97\u3057\u307e\u3059\u3002\u73fe\u5728\u9032\u884c\u4e2d\u306e\u7814\u7a76\u306f\u3001\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u3068\u4ed6\u306e\u6cbb\u7642\u6cd5\u3092\u7d44\u307f\u5408\u308f\u305b\u308b\u3053\u3068\u3067\u3053\u306e\u554f\u984c\u3092\u514b\u670d\u3059\u308b\u3053\u3068\u306b\u7126\u70b9\u3092\u5f53\u3066\u3066\u3044\u307e\u3059\u3002<\/li>\n<li>\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0\u3068\u526f\u4f5c\u7528\uff1a\u5fcd\u5bb9\u6027\u306f\u826f\u597d\u3067\u3059\u304c\u3001\u60a3\u8005\u306f\u5fc3\u7b4b\u75c7\u3084QT\u9593\u9694\u5ef6\u9577\u306a\u3069\u306e\u526f\u4f5c\u7528\u306b\u3064\u3044\u3066\u5b9a\u671f\u7684\u306a\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0\u304c\u5fc5\u8981\u3067\u3059\u3002\n<\/li>\n<\/ul>\n<h2>\u5c06\u6765\u306e\u5c55\u671b\uff1a\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u306e\u6b21\u306a\u308b\u5c55\u958b\u306f\uff1f<\/h2>\n<p>\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u306e\u5c06\u6765\u306f\u6709\u671b\u3067\u3059\u3002\u9032\u884c\u4e2d\u306eFLAURA2\u8a66\u9a13\u3001\u4ed6\u306e\u6cbb\u7642\u6cd5\u3068\u306e\u4f75\u7528\u3001\u304a\u3088\u3073\u8853\u5f8c\u88dc\u52a9\u7642\u6cd5\u3068\u3057\u3066\u306e\u4f7f\u7528\u306b\u95a2\u3059\u308b\u3055\u3089\u306a\u308b\u63a2\u6c42\u306b\u3088\u308a\u3001\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u306fEGFR\u5909\u7570NSCLC\u3068\u306e\u95d8\u3044\u306b\u304a\u3044\u3066\u5f15\u304d\u7d9a\u304d\u91cd\u8981\u306a\u5f79\u5272\u3092\u679c\u305f\u3059\u3068\u4e88\u60f3\u3055\u308c\u307e\u3059\u3002FDA\u306f\u3053\u308c\u3089\u306e\u8a66\u9a13\u7d50\u679c\u3092\u7dbf\u5bc6\u306b\u76e3\u8996\u3057\u3066\u304a\u308a\u3001\u65b0\u305f\u306a\u627f\u8a8d\u304c\u9593\u8fd1\u306b\u8feb\u3063\u3066\u304a\u308a\u3001\u73fe\u5728\u306e\u9069\u5fdc\u75c7\u3092\u8d85\u3048\u3066\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u306e\u4f7f\u7528\u304c\u62e1\u5927\u3059\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002<\/p>\n<h2>\u6700\u5f8c\u306b<\/h2>\n<p>2024\u5e74\u3001\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u306fEGFR\u5909\u7570NSCLC\u306e\u4e00\u6b21\u6cbb\u7642\u3068\u3057\u3066\u5f15\u304d\u7d9a\u304d\u6ce8\u76ee\u3092\u96c6\u3081\u3066\u304a\u308a\u3001\u5f93\u6765\u306e\u6cbb\u7642\u6cd5\u3088\u308a\u3082\u6a19\u7684\u3092\u7d5e\u3063\u305f\u3001\u52b9\u679c\u7684\u3067\u5b89\u5168\u306a\u9078\u629e\u80a2\u3092\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002FDA\u627f\u8a8d\u306e\u30b9\u30c6\u30fc\u30bf\u30b9\u3068\u9032\u884c\u4e2d\u306e\u81e8\u5e8a\u7814\u7a76\u306b\u3088\u308a\u3001\u4eca\u5f8c\u4f55\u5e74\u306b\u3082\u308f\u305f\u3063\u3066\u500b\u5225\u5316\u304c\u3093\u6cbb\u7642\u306b\u304a\u3044\u3066\u6975\u3081\u3066\u91cd\u8981\u306a\u5f79\u5272\u3092\u679c\u305f\u3059\u3053\u3068\u304c\u4fdd\u8a3c\u3055\u308c\u3066\u3044\u307e\u3059\u3002<br \/>\n\t\t\t\u3053\u306e\u30d6\u30ed\u30b0\u306f\u60c5\u5831\u63d0\u4f9b\u306e\u307f\u3092\u76ee\u7684\u3068\u3057\u3066\u304a\u308a\u3001\u5c02\u9580\u7684\u306a\u533b\u7642\u30a2\u30c9\u30d0\u30a4\u30b9\u306e\u4ee3\u308f\u308a\u3068\u898b\u306a\u3055\u308c\u308b\u3079\u304d\u3067\u306f\u3042\u308a\u307e\u305b\u3093\u3002\u6cbb\u7642\u306b\u5909\u66f4\u3092\u52a0\u3048\u308b\u524d\u306b\u3001\u5fc5\u305a\u533b\u7642\u63d0\u4f9b\u8005\u306b\u3054\u76f8\u8ac7\u304f\u3060\u3055\u3044\u3002<\/p>\n<h2 style=\"font-weight: 500\"><strong>\u60c5\u5831\u6e90\uff1a<\/strong><\/h2>\n<p>\t\t\tNew England Journal of Medicine (NEJM): FLAURA\u8a66\u9a13<\/p>\n<p>ASCOPost:<a href=\"https:\/\/ascopost.com\/news\/february-2024\/fda-approves-osimertinib-with-chemotherapy-for-egfr-mutated-nsclc\/\" rel=\"nofollow noopener\" target=\"_blank\">\u00a0\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u306eFDA\u627f\u8a8d<\/a><\/p>\n<p>\t\t\t\u7c73\u56fd\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\uff08ASCO\uff09\uff1a\u80ba\u304c\u3093\u6cbb\u7642\u306e\u6700\u65b0\u60c5\u5831<\/p>\n<p>FDA:\u00a0<a href=\"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-osimertinib-chemotherapy-egfr-mutated-non-small-cell-lung-cancer\" rel=\"nofollow noopener\" target=\"_blank\">\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u306e\u6700\u8fd1\u306e\u627f\u8a8d\u3068\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u306f\u3001EGFR\u5909\u7570\u975e\u5c0f\u7d30\u80de\u80ba\u304c\u3093\uff08NSCLC\uff09\u306e\u6cbb\u7642\u306b\u304a\u3051\u308b\u9769\u65b0\u7684\u306a\u85ac\u5264\u3067\u3042\u308a\u3001\u816b\u760d\u5b66\u306e\u5206\u91ce\u3067\u6ce8\u76ee\u3092\u96c6\u3081\u3066\u3044\u307e\u3059\u3002\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u306f\u30bf\u30b0\u30ea\u30c3\u30bd\u3068\u3057\u3066\u3082\u77e5\u3089\u308c\u3066\u3044\u307e\u3059\u3002\u5f53\u521d\u306f\u8010\u6027\u306e\u3042\u308b\u80ba\u304c\u3093\u60a3\u8005\u306b\u5bfe\u3059\u308b\u4e8c\u6b21\u6cbb\u7642\u3068 [&hellip;]<\/p>\n","protected":false},"author":124,"featured_media":137043,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6123,6123,6561,6561],"tags":[],"class_list":["post-39193","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer-medicine","category-fda-approval-clinical-trials"],"_links":{"self":[{"href":"https:\/\/indogenmed.org\/ja\/wp-json\/wp\/v2\/posts\/39193","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/indogenmed.org\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/indogenmed.org\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/indogenmed.org\/ja\/wp-json\/wp\/v2\/users\/124"}],"replies":[{"embeddable":true,"href":"https:\/\/indogenmed.org\/ja\/wp-json\/wp\/v2\/comments?post=39193"}],"version-history":[{"count":0,"href":"https:\/\/indogenmed.org\/ja\/wp-json\/wp\/v2\/posts\/39193\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/indogenmed.org\/ja\/wp-json\/wp\/v2\/media\/137043"}],"wp:attachment":[{"href":"https:\/\/indogenmed.org\/ja\/wp-json\/wp\/v2\/media?parent=39193"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/indogenmed.org\/ja\/wp-json\/wp\/v2\/categories?post=39193"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/indogenmed.org\/ja\/wp-json\/wp\/v2\/tags?post=39193"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}